Zhi Tong Cai Jing·2025-08-11 12:39Core Viewpoint - China Biologic Products (01177) has received acceptance from the National Medical Products Administration (NMPA) for the clinical trial application of its innovative drug TQB3122, a PARP1 inhibitor intended for the treatment of advanced malignant tumors [1] Group 1: Product Details - TQB3122 is a highly selective PARP1 inhibitor with the ability to penetrate the blood-brain barrier, demonstrating anti-tumor effects through a dual mechanism [1] - The drug competitively inhibits the catalytic activity of the PARP1 enzyme, blocking DNA single-strand break repair, and stabilizes the DNA-PARP complex to hinder replication fork progression [1] - Based on the principle of "synthetic lethality," TQB3122 selectively targets tumor cells with BRCA mutations or homologous recombination deficiencies [1] Group 2: Clinical Potential - Research indicates that TQB3122 shows significant efficacy across multiple tumor models and has outstanding distribution capabilities in brain tissue, making it a potential new option for treating intracranial tumors [1] - Currently, there are no approved drugs targeting the same mechanism globally, positioning TQB3122 as a novel therapeutic choice for patients with advanced solid tumors [1]